Authors

• Adam Charles Harvey (ORCID: https://orcid.org/0000-0002-6154-7881)
• Lindy Bancke
• Thomas Louie (ORCID: https://orcid.org/0000-0003-2131-0158)
• Beth Guthmueller
• Erik R. Dubberke (ORCID: https://orcid.org/0000-0003-3779-2796)
• Paul Feuerstadt (ORCID: https://orcid.org/0000-0002-7643-9576)
• Sahil Khanna (ORCID: https://orcid.org/0000-0002-7619-8338)
• Robert Orenstein (ORCID: https://orcid.org/0000-0001-5210-1258)
• Frederikke Hoeyer
• Christine Lee (ORCID: https://orcid.org/0000-0002-0014-7788)

Institutions

• University of British Columbia (CA)
• University of Calgary (CA)
• Washington University in St. Louis (US)
• University of Victoria (CA)
• Yale University (US)
• Ferring Pharmaceuticals (United States) (US)
• Mayo Clinic in Arizona (US)
• Mayo Clinic Hospital (US)
• Ferring Pharmaceuticals (Denmark) (DK)
• Gastroenterology Center of Connecticut (US)

Publication Details

Journal

Therapeutic Advances in Gastroenterology

Published

2025-11-01

DOI

https://doi.org/10.1177/17562848251395566

Primary Topic

Clostridium difficile and Clostridium perfringens research

Type

article

Field-Weighted Citation Impact

0.00